Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

Phase 4 Completed 100 enrolled PETHEMA Foundation

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To reproduce or to improve the index of complete responses of protocol LMA-91 with a similar protocol, decreasing the dose of Idarubicin to try to reduce the deaths in induction

Timeline

Start: 1998-10
Primary completion: 2008-12
Completion: 2008-12

Publications

Martinez-Lopez J, Fernandez-Redondo E, Garcia-Sanz R, Montalban MA, Martinez-Sanchez P, Pavia B, Mateos MV, Rosinol L, Martin M, Ayala R, Martinez R, Blanchard MJ, Alegre A, Besalduch J, Bargay J, Hernandez MT, Sarasquete ME, Sanchez-Godoy P, Fernandez M, Blade J, San Miguel JF, Lahuerta JJ; GEM (Grupo Espanol Multidisciplinar de Melanoma)/PETHEMA (Programa para el Estudio de la Terapeutica en Hemopatias Malignas) cooperative study group. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. Br J Haematol. 2013 Dec;163(5):581-9. doi: 10.1111/bjh.12576. Epub 2013 Oct 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cytarabine	Small molecule	100 mg/m2	—
Subject	Cytarabine	Small molecule	500 mg/m2	—
Subject	Idarubicin	Small molecule	8 mg/m2	—
Background	Molgramostim	Protein / enzyme biologic	5 ug/kg	Subcutaneous

Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

Summary

Timeline

Publications

Drugs

Indications